(ACTU) Actuate Therapeutics Inc SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ACTU) Actuate Therapeutics Inc Complete Analysis Pack
Your Credibility Toolkit Starts Here
This Actuate Therapeutics Inc SWOT Analysis distills the company’s strengths, weaknesses, opportunities, and threats into a concise, actionable framework for research, strategy, or investment work; the page already contains a real preview/sample of the report so you can judge style and substance. Purchase the full version to download the complete ready-to-use analysis instantly.
Strengths
1 lead asset: Elraglusib
Actuate Therapeutics is built around one lead asset, Elraglusib Injection, a glycogen synthase kinase-3 (GSK-3) inhibitor with a differentiated oncology mechanism. That focus can direct capital, trials, and management time into one program; Actuate Therapeutics reported about $8.7 million in cash and cash equivalents at June 30, 2024. A single-asset model can speed decisions and sharpen development spend.
4 cancer indications
Elraglusib’s four indications—metastatic pancreatic ductal adenocarcinoma, Ewing sarcoma, metastatic melanoma, and colorectal cancer—give Actuate Therapeutics multiple shots on goal from one molecule. That broadens reach across both rare and large oncology markets, not just one tumor type. It also targets high-unmet-need cancers; pancreatic cancer still has about a 13% 5-year relative survival rate overall, underscoring the value of new options.
2015 founding
Actuate Therapeutics was founded in 2015 and rebranded in October 2015, giving it a clear corporate origin and focused development path. By 2026, it has moved beyond discovery into the clinical stage, centered on its lead asset elraglusib. That history matters: a 10-year operating runway is longer than many early biotech peers, but still young enough to stay agile.
High-unmet-need oncology focus
Actuate Therapeutics Inc is focused on metastatic pancreatic ductal adenocarcinoma, a disease with about 66,440 new U.S. pancreatic cancer cases and 51,750 deaths expected in 2025. This stage has a 5-year relative survival near 3%, so even small efficacy gains can matter a lot. That makes any positive signal more visible and more valuable for clinical and commercial upside.
- High unmet need lifts trial relevance
- Positive data can drive strong value
- Small gains may stand out fast
Single-platform efficiency
Actuate Therapeutics Inc is built around one asset, Elraglusib, so its R&D, manufacturing, and scientific message stay focused. That single-platform setup can cut complexity and make partner talks cleaner, since the story is just one program and one mechanism. For a precommercial biotech, that kind of focus can matter more than a broad but scattered pipeline.
- 1 core platform: Elraglusib
- Simpler development and CMC
- Clearer partnering story
Actuate’s Focused Bet on Elraglusib Sets Up a Clear Oncology Play
Actuate Therapeutics Inc’s main strength is its focused clinical bet on Elraglusib Injection, a glycogen synthase kinase-3 inhibitor that has clear oncology differentiation. That single-asset model keeps R&D and messaging tight, which matters for a precommercial biotech. Elraglusib also spans four targets: pancreatic cancer, Ewing sarcoma, melanoma, and colorectal cancer.
| Strength | Data |
|---|---|
| Cash | $8.7M at Jun 30, 2024 |
| Lead asset | Elraglusib |
| Targets | 4 indications |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Actuate Therapeutics Inc’s business strategy
Editable Excel File
Delivers a quick SWOT snapshot for Actuate Therapeutics Inc, easing strategic analysis and decision-making.
Reference Sources
Consolidates primary industry reports, clinical data, and trusted benchmarks to speed due diligence and link each key claim to traceable references.
Weaknesses
0 approved products
Actuate Therapeutics remains a clinical-stage biopharmaceutical company with 0 approved products and no marketed product revenue, so it still depends on future trial and regulatory wins. In its latest reported results, revenue stayed at $0, while R&D spending and cash burn kept the business tied to capital raises rather than sales. That leaves Actuate Therapeutics exposed to binary clinical risk until a drug is approved and commercialized.
1 main pipeline asset
Actuate Therapeutics Inc is heavily tied to Elraglusib, its lead and near-only pipeline asset, so the company has clear concentration risk. If the drug misses key trial endpoints or safety targets, the hit can be severe because there is no broad late-stage pipeline to absorb the blow. In small biotech, one asset often means one shot at value creation.
Clinical-stage risk
Actuate Therapeutics Inc. remains exposed to clinical-stage risk because Elraglusib has not yet shown approved-drug proof, and efficacy or safety can still fail in late trials. In oncology, only about 1 in 10 drug candidates entering clinical development reaches approval, so late-stage attrition can quickly reset timelines and value.
Capital dependence
Actuate Therapeutics Inc has a clear capital dependence weakness because oncology trials are costly, and a Company Name with no commercial sales must fund R&D through outside capital. That often means more share dilution or higher borrowing costs, especially if trial timelines slip or burn rate rises. The risk is sharper in biotech, where late-stage study spend can reach tens of millions of dollars.
- No product revenue yet
- Trial spend is cash-heavy
- Financing can dilute holders
- Debt can add pressure
Narrow operating scale
Actuate Therapeutics is still far smaller than major oncology developers, so its narrow scale can stretch staff, cash, and vendor capacity across trials, manufacturing, and launch prep. One delayed study readout can hit harder when there is no large pipeline to absorb the slip.
That lower scale can also limit bargaining power with CROs, CMOs, and distributors, which raises execution risk and can slow commercialization planning.
- Smaller team, fewer backup programs
- Less room for trial delays
- Weaker leverage with partners
Actuate's Biggest Risk: No Sales, One Drug
Actuate Therapeutics Inc has no approved products and no product revenue, so it still depends on trial success and outside funding. Its weakness is also concentration: Elraglusib is the near-only asset, so one late-stage setback can wipe out most value. As a small clinical-stage Company Name, it has limited cash cushion and higher dilution risk.
| Weakness | Data point |
|---|---|
| No sales | $0 revenue |
| Asset concentration | 1 lead program |
| Commercial gap | 0 approved products |
Full Version Awaits
Actuate Therapeutics Inc Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and reflects key strengths, weaknesses, opportunities, and threats for Actuate Therapeutics Inc.
Opportunities
4 named indication paths
Elraglusib has 4 named cancer paths in development, so one molecule can drive multiple shots on goal. If Company Name wins in 1 indication, it could help validate the same biology in the other 3 and lift the platform’s odds. That can create more than one value trigger without a new drug each time.
Pancreatic cancer expansion
Metastatic pancreatic ductal adenocarcinoma remains a major unmet need, with 5-year survival near 3% in the U.S. and about 67,440 new pancreatic cancer cases expected in 2025. Even modest gains can be valuable because current first-line regimens still leave median overall survival measured in months, not years. Positive data from Actuate Therapeutics Inc could be a major value inflection.
Rare cancer upside
Ewing sarcoma is a rare oncology niche, with about 200 to 250 new U.S. cases a year and few effective options after relapse. In rare diseases, cleaner endpoints and small trials can speed development and help Actuate Therapeutics stand out if its data are strong. A real win here would also boost scientific credibility across its cancer pipeline.
Combination therapy potential
Elraglusib’s best opportunity is as a combo add-on to standard oncology regimens, since most cancer care already uses two-drug or three-drug therapy. In metastatic pancreatic cancer, gemcitabine plus nab-paclitaxel delivered median overall survival of 8.5 months in the MPACT trial, showing why stronger combinations matter. If Elraglusib lifts response or survival, it can fit more easily into routine treatment pathways.
- Fits common oncology combo care
- Could boost response rates
- May support standard-pathway use
Partnering and licensing
Actuate Therapeutics Inc can cut risk by partnering or licensing with larger oncology companies that bring cash, trial know-how, and global sales reach. That can lower burn while helping the asset move faster through development and into more markets.
In oncology, deals often include upfront cash plus milestone payments, so even one license can fund later trials without heavy dilution. A strong partner can also add regulatory and commercial scale that a small biotech cannot build alone.
- Reduces financing pressure
- Expands market access
- Speeds trial execution
- Improves deal credibility
Actuate’s Multi-Path Cancer Bet Could Unlock Big Upside
Actuate Therapeutics Inc’s main upside is that elraglusib can test in 4 named cancer paths, so one win can validate more than one program. Metastatic pancreatic ductal adenocarcinoma still has about a 3% 5-year U.S. survival rate and 67,440 expected new cases in 2025, so even small gains can matter. Ewing sarcoma adds rare-disease speed and cleaner trial readouts.
| Opportunity | Why it matters | Data point |
|---|---|---|
| Pancreatic cancer | Large unmet need | 67,440 cases in 2025 |
| Ewing sarcoma | Rare, faster readouts | 200-250 U.S. cases yearly |
Threats
1 trial failure risk
Actuate Therapeutics faces high trial-failure risk because its pipeline is tightly concentrated around elraglusib, so one negative readout could hit valuation hard. In oncology, even late-stage studies often miss the bar, and many programs fail on overall survival or progression-free survival endpoints. A setback could stall development for 12-24 months, force redesigns, and weaken financing leverage.
Intense oncology competition
Pancreatic cancer, melanoma, and colorectal cancer are all crowded drug-development arenas, with 2025 U.S. case counts of about 67,440, 104,960, and 154,270, respectively, drawing heavy R&D spend. Larger peers can fund more trials and faster launches, so Actuate Therapeutics Inc faces tough differentiation pressure. Ewing sarcoma is rarer, but even here active programs can still crowd share.
Regulatory uncertainty
Actuate Therapeutics Inc faces high regulatory risk because new oncology drugs are reviewed closely for safety, dose, and efficacy. Regulators can ask for more follow-up or extra data, which can slow the path to approval.
Any unexpected adverse event in late-stage trials can trigger a hold or force new studies. For a small biotech, even a few months of delay can pressure funding and shift the approval timeline.
Funding and dilution risk
Actuate Therapeutics needs steady cash to fund trials, and clinical-stage biotech burn rates often run for 12 to 24 months of runway at a time. If capital markets tighten, the Company may have to raise money at a lower share price, which raises dilution risk for current holders.
- Trial spend keeps cash needs high
- Tighter markets can force cheap raises
- New equity can cut per-share value
Execution delays
Execution delays are a real threat for Actuate Therapeutics, Inc. Trial enrollment, site activation, manufacturing, and data readouts can all slip, and oncology programs often face long, variable timelines before a clear value inflection point. Longer timelines can also raise cash burn and force extra financing, which adds pressure on a small clinical-stage balance sheet.
Slower enrollment delays readouts.
Manufacturing issues can stall dosing.
Longer timelines increase funding needs.
Actuate Faces High Trial Risk and Possible Dilution
Actuate Therapeutics Inc is exposed to high binary trial risk because elraglusib drives most value, so one bad readout could cut the story fast. Oncology rivals are deep-pocketed, and 2025 U.S. case counts were about 67,440 pancreatic, 104,960 melanoma, and 154,270 colorectal, keeping competition intense. Cash burn, delays, and regulatory asks can force dilution or push approval back 12-24 months.
| Threat | Key data |
|---|---|
| Pipeline concentration | 1 main asset |
| Market competition | 2025 cases: 67,440; 104,960; 154,270 |
| Delay risk | 12-24 months |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.